Nath Bio-Genes (India) Ltd schedules board meeting to approve unaudited FY2026 results

What Nath Bio-Genes (India) Ltd announced

Nath Bio-Genes (India) Ltd filed a notice with the Bombay Stock Exchange (BSE) on 18 July 2026, informing shareholders that the Board of Directors will convene on 29 July 2026. The primary agenda of the meeting is to consider and approve the unaudited financial results for the period ending 30 June 2026.

The notice does not provide any quantitative details of the financial performance, nor does it indicate whether any other items will be discussed.

Board meeting details

• Date of meeting: 29 July 2026
• Purpose: Approval of unaudited financial results as of 30 June 2026
• Filing date: 18 July 2026 (10:41:46 UTC)
• Exchange: BSE (code 537291)
• NSE ticker: Not applicable / not listed

The company has complied with the listing regulations that require a minimum 48‑hour notice for board meetings where financial results are to be approved. No further agenda items, such as dividend declarations or corporate restructuring, were disclosed in the filing.

Unaudited financial results

The filing explicitly states that the results are unaudited. This is a standard practice for interim or quarterly results, which are later subjected to a formal audit before being presented in the annual report. As of the filing date, the company has not released any figures such as revenue, profit, or cash flow.

Investors should note that unaudited numbers are preliminary and may be adjusted after the audit process. The board’s approval is a procedural step that enables the company to publish the results to the market and comply with regulatory reporting timelines.

Key facts at a glance

Why this matters for investors

The board’s approval of unaudited results is a regulatory requirement that allows the company to disclose its interim performance to shareholders and the market. While the filing does not reveal the actual numbers, the approval signals that the company is on track with its reporting schedule. Investors should await the subsequent release of the financial figures, which will provide insight into revenue growth, profitability, and cash position for the quarter.

Conclusion

Nath Bio-Genes (India) Ltd has scheduled a board meeting on 29 July 2026 to approve its unaudited financial results for the quarter ended 30 June 2026. No financial details were disclosed in the notice, and the results remain unaudited pending the formal audit process. Stakeholders should monitor future disclosures for the actual performance metrics.